ADVANCE-ID is pleased to share a significant milestone in the Phase 2b RIV-CARE clinical trial, following BioVersys’ announcement on 29 October 2026 of the first patient first visit in the study. RIV-CARE is an open-label Phase …
ADVANCE-ID marked a significant milestone on 31 August 2026 with the official launch of its designation as a World Health Organization (WHO) Collaborating Centre for Clinical Trials, reinforcing its commitment to strengthening clinical research capacity and …